Claire McCaskill

It appears to me that the books are being presented in a way to give the impression that this is about R&D.

Did he have any--how about Michael Pearson at Valeant? Did he have that kind of background?

Retrophin is a company that spends significant amounts of money on R&D in particular.

I do not think anybody buys a $2 million album of Wu-Tang if they do not have any cash on hand.

You became CEO--you were Chairman of the Board beginning at the beginning of this adventure to acquire Daraprim and jack the price up because there was nothing anybody could do about it.

Funny that these small companies still haven't realized you can raise price aggressively and nobody gets too upset.

Senator McCaskill. Let me first turn to Mr. Tilles about R&D.

I thought you just said that this was a growing epidemic worldwide, globally, and that this need for this drug was so serious compared to what had been prescribed.

How do we trust anything you tell us about your revenue or your R&D expenditure if you do not understand basic terms of pharmaceutical industry at your deposition and you do not even understand what your sales are?

Well, I get confused. On one hand, you say that you are going to do groundbreaking R&D with 60 percent of your revenues, and you turn around and say, well, we are a very small company. We only have three or four people.

I think that the essence of these e-mails, if you look at all of these e-mails, is that you are really engaged with Mr. Shkreli back and forth, I mean, minute by minute.

We need to figure out how to get at protecting families like the Weston family when there is a life saving drug, but not a lot of people need it, because they are the ones that are really getting it stuck to them.

I do not know how that helps get more people the drug. It is counterintuitive.

SUDDEN PRICE SPIKES IN DECADES-OLD PRESCRIPTION DRUGS: INSIDE THE MONOPOLY BUSINESS MODEL

Which, of course, saves us money. When we figure out something is not ready for prime time, then we do not chase bad money after good.

It would be a shame for us to lose this capability because one branch says not us and the other branch says not us.

We are manning, equipping, and protecting our soldiers. We know that. We are not talking about testing for something that is not directly relevant to doing what we are asking our soldiers to do.

Has this been completed?

What actions have been taken to improve security controls at Camp Arifjan?

Modernizing the Lifeline program to cover broadband service as opposed to basic phone service is a worthy goal and one I support in concept if accompanied by appropriate structural reforms to the program.

With today's Russian influence and aggression from multiple directions, increased requirements to reassure our European allies and partners...

My prognoses is good and I expect a full recovery.

If U.S. Southern Command and U.S. Northern Command were combined into one command, would the Commander be able to execute the missions and requirements of both commands?

You've stated the Navy has a strike fighter inventory issue. Last year, the President's Budget requested no funding to procure Super Hornets, yet the Congress funded five Super Hornets in the fiscal year 2016 Omnibus.

That seems awfully high civilian, which I understand how it happened and why it happened, but shouldn't we try to reverse that?